Filing Details

Accession Number:
0001209191-10-044850
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-09-02 14:38:01
Reporting Period:
2010-09-01
Filing Date:
2010-09-02
Accepted Time:
2010-09-02 14:38:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
901219 Human Genome Sciences Inc HGSI In Vitro & In Vivo Diagnostic Substances (2835) 223178468
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1332456 Barry Labinger 14200 Shady Grove Road
Rockville MD 20850
Exec Vp & Cco No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-09-01 50,000 $4.92 50,000 No 4 M Direct
Common Stock Disposition 2010-09-01 50,000 $30.02 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee stock option right to buy Disposition 2010-09-01 50,000 $0.00 50,000 $4.92
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
70,871 2018-03-10 No 4 M Direct
Footnotes
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and Charles Schwab effective 6/16/10.
  2. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.06. The price reported above reflects the weighted average sales price. Upon written request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price is available.
  3. One-eighth of the 150,000 options granted on March 10, 2008, vested on the six-month anniversary date (September, 2008) and the remaining options granted vested and continue to vest monthly on a ratable basis for the next 42 months commencing on October 10, 2008.